
Opinion|Videos|September 30, 2024
Emerging Research of RNAi-Based Therapies for FCS
Panelists discuss how early diagnosis and intervention in familial chylomicronemia syndrome (FCS) are crucial for preventing cardiovascular and metabolic complications, emphasizing the key role clinicians play in initiating timely and effective treatment strategies.
Advertisement
Video content above is prompted by the following:
What are the benefits of early diagnosis and intervention in familial chylomicronemia syndrome for preventing cardiovascular and metabolic complications, and what role do clinicians play in this process?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 07/19
2
FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD
3
Can We Stop Heart Failure at Its Source?
4
Sanofi Announces Discontinuation of Amlitelimab for Atopic Dermatitis
5







































































